Sort
39,280 grants matching “leukemia”
Incorporating FLT3 inhibitors into AML treatment regimens
$330,091Mark J Levis · Johns Hopkins University · R01 · FY2012 · CA
Immunologic targets in Myeloid Leukemia
$330,091Hyam Isaac Levitsky · Johns Hopkins University · R01 · FY2011 · CA
ETIOLOGY &PATHOGENESIS OF MURINE GRAFT VS-HOST DISEASE
$330,086Thomas Jefferson University · R01 · FY2003 · HL
Shwachman-Diamond Syndrome: Molecular Pathogenesis
$330,057Akiko Shimamura · Boston Children'S Hospital · R01 · FY2006 · HL
Proteomic Approach to Further Understanding the Role of*
$330,057Alan B. Cantor · Boston Children'S Hospital · R01 · FY2006 · HL
Optimizing the graft versus leukemia effect for pediatric ALL
$330,006Terry Fry · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
The role of DOT1L methyltransferase in controlling the noncoding transcriptome
$330,000Alla Grishok · Boston University Medical Campus · R01 · FY2023 · GM
IMMUNOGENOMICS OF GRAFT VS HOST DISEASE
$330,000Jackson Laboratory · R01 · FY2000 · HL
Maintenance therapy with decitabine for acute myeloid leukemia in first remission
$330,000William G Blum · Ohio State University · R21 · FY2010 · CA
Immunoglobulin and T Cell Receptor Gene Assembly
$330,000David G. Schatz · Yale University · R37 · FY2007 · AI
IMMUNOGENOMICS OF GRAFT VS HOST DISEASE
$330,000Jackson Laboratory · R01 · FY2002 · HL
The role of DOT1L methyltransferase in controlling the noncoding transcriptome
$330,000Alla Grishok · Boston University Medical Campus · R01 · FY2020 · GM
IMMUNOGENOMICS OF GRAFT VS HOST DISEASE
$330,000Jackson Laboratory · R01 · FY2001 · HL
The role of DOT1L methyltransferase in controlling the noncoding transcriptome
$330,000Alla Grishok · Boston University Medical Campus · R01 · FY2022 · GM
IMMUNOGENOMICS OF GRAFT VS HOST DISEASE
$330,000Jackson Laboratory · R01 · FY2003 · HL
The role of DOT1L methyltransferase in controlling the noncoding transcriptome
$330,000Alla Grishok · Boston University Medical Campus · R01 · FY2021 · GM
Maintenance therapy with decitabine for acute myeloid leukemia in first remission
$330,000William G Blum · Ohio State University · R21 · FY2009 · CA
Presenilins in tumorigenesis and neurodegeneration
$329,997Hui Zheng · Baylor College Of Medicine · R01 · FY2007 · NS
Mechanism of Pancreatic Carcinogenesis
$329,991Martin Ernesto Fernandez-Zapico · Mayo Clinic Rochester · R01 · FY2019 · CA
Histone Modification and Changes in Chromatin: Silencing of Tumor Suppressor Gene
$329,978Mark R Parthun · Ohio State University · P01 · FY2008 · CA
Turning off the molecular switch for pathological self-assembly of FUS
$329,957Nicolas Lux Fawzi · Brown University · R01 · FY2020 · GM
Immunobiology of Hybrid Resistance
$329,940University Of Texas Sw Med Ctr/Dallas · R01 · FY2004 · CA
Immunobiology of Hybrid Resistance
$329,940University Of Texas Sw Med Ctr/Dallas · R01 · FY2003 · CA
Immunobiology of Hybrid Resistance
$329,940University Of Texas Sw Med Ctr/Dallas · R01 · FY2005 · CA
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
$329,925Peter D. Cole · Rbhs -Cancer Institute Of New Jersey · R01 · FY2018 · CA